MedTrace Logo

Cardiovascular Prevention for Persons With HIV

NCT00982189 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 37

Last updated 2017-11-22

Study results available
· View outcomes & findings →

Summary

This study is funded by the American Heart Association. The goal of this research is to prevent early cardiovascular damage before symptoms develop for persons with HIV infection. Evidence suggests that taking low doses of blood pressure and cholesterol medication reduces risk for heart disease in persons who are at increased risk (such as the case with HIV infection).

Participants who are taking HIV treatment with an 'undetectable' viral load, and who do NOT need treatment for high blood pressure or cholesterol may be eligible to enroll. Participants will take a low dose cholesterol medication (or placebo) and a low dose of a blood pressure medication (or a placebo), and will be seen at 3 study visits over 4 months.

Conditions

  • HIV Infection
  • Cardiovascular Disease Risk

Interventions

DRUG

Pravastatin

Participants randomized to take pravastatin (active) or matching placebo pill once daily

DRUG

Lisinopril

Participants randomized to take lisinopril (active) or matching placebo pill once daily

Sponsors & Collaborators

Principal Investigators

  • Jason Baker, MD · Hennepin Faculty Associates

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
DOUBLE
Model
FACTORIAL

Eligibility

Min Age
40 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-09-30
Primary Completion
2010-12-31
Completion
2011-05-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00982189 on ClinicalTrials.gov